Reviews
29 January 2025
Early Access
Venous thromboembolism in bullous pemphigoid: current evidence and update on systematic review
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
346
Views
189
Downloads
Authors
Various studies have shown that individuals with bullous pemphigoid (BP) are more likely to develop venous thromboembolism (VTE). However, it is important to acknowledge that these studies primarily focused on individuals in Western nations, which restricts their generalization to a wider demographic. The present systematic review aims to assess the cumulative risk of VTE in individuals with BP compared to healthy individuals. PubMed, Cochrane, and Scopus databases were searched for evidence-based research papers on BP and VTE. Eligibility criteria were based on the PICOS criteria. The Newcastle-Ottawa scale assessed methodological quality. After database searches, 115 studies meeting the inclusion criteria were identified. A manual inquiry yielded an additional 11 articles. After removing duplicates (n=54), 72 publications underwent title and abstract evaluation, resulting in the exclusion of 44 manuscripts. Consequently, the remaining full-text articles were thoroughly examined. Following full-text screening, 9 publications were included. The studies were conducted in Denmark, the USA, the UK, Taiwan, and Italy. The findings enhanced the generalizability of the correlation between VTE and BP. Individuals with systemic autoimmune diseases were found to have a 1.5 to 4 times higher likelihood of developing VTE. The analysis revealed that patients with pemphigus face a twofold higher risk of VTE, especially within the first few years after diagnosis. These results may enhance the recognition of pulmonary embolism in BP patients and motivate the prevention of secondary risk markers associated with VTE. Given the morbidity, VTE risk in BP patients warrants greater attention in public healthcare.
Altmetrics
Downloads
Download data is not yet available.
Citations
Ungprasert P, Wijarnpreecha K, Thongprayoon C. Risk of venous thromboembolism in patients with bullous pemphigoid: A systematic review and meta-analysis. Indian J Dermatol Venereol Leprol 2018;84:22–6. DOI: https://doi.org/10.4103/ijdvl.IJDVL_827_16
Moro F, Fania L, Sinagra JLM, et al. Bullous pemphigoid: Trigger and predisposing factors. Biomolecules 2020;10:1432. DOI: https://doi.org/10.3390/biom10101432
Kridin K, Shihade W, Bergman R. Mortality in patients with bullous pemphigoid: A retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol 2018;99:72–7. DOI: https://doi.org/10.2340/00015555-2930
Persson MS, Begum N, Grainge MJ, et al. The global incidence of bullous pemphigoid: a systematic review and meta-analysis. Br J Dermatol 2022;186:414–25. DOI: https://doi.org/10.1111/bjd.20743
Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune diseases: A narrative review with emphasis on primary systemic vasculitides. Vasc Med 2015;20:369–76. DOI: https://doi.org/10.1177/1358863X15573838
Hsu CH, Hsu CK. Beyond the Surface: Investigating the Relationship Between Autoimmune Blistering Disorders and Venous Thromboembolism. J Am Heart Assoc 2023;12:e031086. DOI: https://doi.org/10.1161/JAHA.123.031086
Langan SM, Hubbard R, Fleming K, West J. A population-based study of acute medical conditions associated with bullous pemphigoid. Br J Dermatol 2009;161:1149–52.
Maqsood MH, Weber BN, Haberman RH, et al. Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials. ACR Open Rheumatol 2022;4:912–22. DOI: https://doi.org/10.1002/acr2.11479
Ferranti M, Gobbo G, Cicogna GT, Alaibac M. A monocentric retrospective observational study of comorbidities in patients affected by autoimmune bullous diseases. In Vivo (Brooklyn) 2020;34:2113–8. DOI: https://doi.org/10.21873/invivo.12016
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. The BMJ 2021;372. DOI: https://doi.org/10.1136/bmj.n71
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5. DOI: https://doi.org/10.1007/s10654-010-9491-z
Chen TL, Huang WT, Loh CH, et al. Risk of Incident Venous Thromboembolism Among Patients With Bullous Pemphigoid or Pemphigus Vulgaris: A Nationwide Cohort Study With Meta-Analysis. J Am Heart Assoc 2023;12:e029740.
Schneeweiss MC, Merola JF, Wyss R, et al. Venous Thromboembolism in Patients With Bullous Pemphigoid. JAMA Dermatol 2023;159:750–6. DOI: https://doi.org/10.1001/jamadermatol.2023.1461
Chen CL, Wu CY, Lyu YS, et al. Association between bullous pemphigoid and risk of venous thromboembolism: A nationwide population-based cohort study. J Dermatol 2022;49:753–61.
Shaheen MS, Silverberg JI. Association of inflammatory skin diseases with venous thromboembolism in US adults. Arch Dermatol Res 2021;313:281–9. DOI: https://doi.org/10.1007/s00403-020-02099-6
Kridin K, Kridin M, Amber KT, et al. The Risk of Pulmonary Embolism in Patients With Pemphigus: A Population-Based Large-Scale Longitudinal Study. Front Immunol 2019;10:1559. DOI: https://doi.org/10.3389/fimmu.2019.01559
Polansky M, Eisenstadt R, DeGrazia T, et al. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol 2019;81:179–86. DOI: https://doi.org/10.1016/j.jaad.2019.03.049
Cugno M, Marzano AV, Bucciarelli P, et al. Increased risk of venous thromboembolism in patients with bullous pemphigoid: The INVENTEP (INcidence of VENous Thromboembolism in bullous Pemphigoid) study. Thromb Haemost 2016;115:193–9. DOI: https://doi.org/10.1160/TH15-04-0309
Marzano AV, Tedeschi A, Polloni I, et al. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. Clin Exp Immunol 2013;171:76–81. DOI: https://doi.org/10.1111/j.1365-2249.2012.04674.x
Johannesdottir SA, Schmidt M, Horváth-Puhó E, Sørensen HT. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: A population-based case-control study. J Thromb Haemost 2012;10:815–21. DOI: https://doi.org/10.1111/j.1538-7836.2012.04666.x
Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: Record-linkage study. BMC Med 2011;9:1. DOI: https://doi.org/10.1186/1741-7015-9-1
Zöller SB, Li X, Sundquist J, et al. Articles Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379:244–93. DOI: https://doi.org/10.1016/S0140-6736(11)61306-8
Savin JA. The events leading to the death of patients with pemphigus and pemphigoid
Br J Dermatol 1979;101:521-34 DOI: https://doi.org/10.1111/j.1365-2133.1979.tb15095.x
Langan SM, Hubbard R, Fleming K, West J. A population-based study of acute medical conditions associated with bullous pemphigoid. Br J Dermatol 2009;161:1149–52. DOI: https://doi.org/10.1111/j.1365-2133.2009.09350.x
Chen T, Lee L, Huang H, et al. Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: a systematic review and meta-analysis. JAMA Dermatol 2022;158:1254–61. DOI: https://doi.org/10.1001/jamadermatol.2022.3516
Chen CL, Wu CY, Lyu YS, et al. Association between bullous pemphigoid and risk of venous thromboembolism: A nationwide population-based cohort study. J Dermatol 2022;49:753-61. DOI: https://doi.org/10.1111/1346-8138.16412
Podolec-Rubiś M, Wołek M, Brzewski P, Wojas-Pelc A. Suspicion of pulmonary embolism during treatment of pemphigoid gestationis. Postepy Dermatol Alergol 2013;30:59–61. DOI: https://doi.org/10.5114/pdia.2013.33381
Nagareddy P, Smyth SS. Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol 2013;20:457–63. DOI: https://doi.org/10.1097/MOH.0b013e328364219d
Xu J, Lupu F, Esmon CT. Inflammation, innate immunity, and blood coagulation. Hamostaseologie 2010;30:5–9. DOI: https://doi.org/10.1055/s-0037-1617146
Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: A systematic Retrospective Study on 1130 patients. Ann Rheum Dis 2009;68:564–7. DOI: https://doi.org/10.1136/ard.2008.099051
Stassen PM, Derks RPH, Kallenberg CGM, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis - Incidence and risk factors. Rheumatology 2008;47:530–4. DOI: https://doi.org/10.1093/rheumatology/ken035
Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) 2006;55:146–9. DOI: https://doi.org/10.1002/art.21704
Cugno M, Tedeschi A, Borghi A, et al. Activation of blood coagulation in two prototypic autoimmune skin diseases: A possible link with thrombotic risk. PLoS One 2015;10:e0129456. DOI: https://doi.org/10.1371/journal.pone.0129456
Marzano AV, Tedeschi A, Berti E, et al. Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin Exp Immunol 2011;165:44–50. DOI: https://doi.org/10.1111/j.1365-2249.2011.04391.x
Marzano AV, Tedeschi A, Fanoni D, et al. Activation of blood coagulation in bullous pemphigoid: Role of eosinophils, and local and systemic implications. Br J Dermatol 2009;160:266–72. DOI: https://doi.org/10.1111/j.1365-2133.2008.08880.x
Echigo T, Hasegawa M, Shimada Y, et al. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch Dermatol Res 2006;298:38–45. DOI: https://doi.org/10.1007/s00403-006-0661-5
Timoteo RP, Da Silva MV, Miguel CB, et al. Th1/Th17-related cytokines and chemokines and their implications in the pathogenesis of pemphigus vulgaris. Mediators Inflamm 2017;2017:7151285. DOI: https://doi.org/10.1155/2017/7151285
Sun CC, Wu J, Wong TT, et al. High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities. Br J Dermatol 2000;143:1235-40. DOI: https://doi.org/10.1046/j.1365-2133.2000.03894.x
Zhang L, Chen Z, Wang L, Luo X. Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol 2023;14:1115083. DOI: https://doi.org/10.3389/fimmu.2023.1115083
Kowalski EH, Kneibner D, Kridin K, Amber KT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev 2019;18:526–34. DOI: https://doi.org/10.1016/j.autrev.2019.03.009
Najem MY, Couturaud F, Lemarié CA. Cytokine and chemokine regulation of venous thromboembolism. J Thromb Haemost 2020;18:1009–19. DOI: https://doi.org/10.1111/jth.14759
Bieber K, Ernst AL, Tukaj S, et al. Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. Exp Dermatol 2017;26:1248–52. DOI: https://doi.org/10.1111/exd.13382
Tedeschi A, Marzano AV, Lorini M, et al. Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2015;29:813–7. DOI: https://doi.org/10.1111/jdv.12464
Echigo T, Hasegawa M, Inaoki M, et al. Antiphospholipid antibodies in patients with autoimmune blistering disease. J Am Acad Dermatol 2007;57:397–400. DOI: https://doi.org/10.1016/j.jaad.2006.07.004
Sagi L, Baum S, Barzilai O, et al. Novel antiphospholipid antibodies in autoimmune bullous diseases. Hum Antibodies 2015;23:27–30. DOI: https://doi.org/10.3233/HAB-140280
Chu KY, Yu HS, Yu S. Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview. J Clin Med 2022;11:3528. DOI: https://doi.org/10.3390/jcm11123528
Yang M, Wu H, Zhao M, et al. The pathogenesis of bullous skin diseases. J Transl Autoimmun 2019;2:100014. DOI: https://doi.org/10.1016/j.jtauto.2019.100014
Hall RP, Streilein RD, Hannah DL, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Investig Dermatol 2013;133:2786–8. DOI: https://doi.org/10.1038/jid.2013.236
Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: What is the role of this agent in 2019? Haematologica 2019;104:1124–35. DOI: https://doi.org/10.3324/haematol.2019.218883
Orsi FA, Lijfering WM, Geersing GJ, et al. Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study. Br J Haematol 2021;193:1194–202. DOI: https://doi.org/10.1111/bjh.17388
Chen TL, Huang WT, Loh CH, et al. Risk of Incident Venous Thromboembolism Among Patients With Bullous Pemphigoid or Pemphigus Vulgaris: A Nationwide Cohort Study With Meta-Analysis. J Am Heart Assoc 2023;12:e029740. DOI: https://doi.org/10.1161/JAHA.123.029740
How to Cite
Venous thromboembolism in bullous pemphigoid: current evidence and update on systematic review. (2025). Dermatology Reports. https://doi.org/10.4081/dr.2025.10257
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
